The identification of immunological biomarkers in kidney cancers

Antonio Lopez-Beltran, Vanessa Henriques, Alessia Cimadamore, Matteo Santoni, Liang Cheng, Thomas Gevaert, Ana Blanca, Francesco Massari, Marina Scarpelli, Rodolfo Montironi

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

The recent approval of several agents have revolutionized the scenario of therapeutic management of metastatic renal cell carcinoma (RCC) allowing us to reach important clinical end points with extended patients' survival. Actually, every new drug approved has represented an important step forward to the improvement of patient's survival. On the other hand, we now understand that RCC includes a large group of tumor entities, each of them with different genetic and mutational alterations, but also showing different clinical behavior; a reason behind the needs of subtype specific personalized approach to therapy of RCC. Immunotherapy is gradually becoming a key factor in the therapeutic algorithm for patients with locally advanced or metastatic RCC. Due to the combination of potent treatment success and potentially deadly adverse effects from immune checkpoint inhibitors (ICI), gathering prognostic and predictive information about FDA-indicated tumors seems to be prudent. Robust and reliable biomarkers are crucial for patient's selection of treatments with immunomodulatory drugs. PD-L1 expression is a poor prognostic factor and predictive of better responses from both PD-1 and PD-L1 inhibitors in a variety of tumor types including RCC. Each FDA approved PD-1/PD-L1 drug is paired with a PD-L1 Immunohistochemistry (IHC) assay. Thus, there is need for improved knowledge and application of PD-1/PD-L1 IHC biomarkers in daily practice. IHC staining appears in membranous fashion. The atezolizumab approved IHC assay is unique in that only immune cell staining is quantified for the use of this assay in RCC. A single biomarker for patient selection may not be feasible, given that immune responses are dynamic and evolve over time. Biomarker development for ICI drugs will likely require integration of multiple biologic components like PD-L1 expression, TILs and mutational load. New methodological approaches based on digital pathology may be relevant since they will allow recognition of the biomarker and to objectively quantitate its expression, and therefore might produce objective and reproducible cut-off assessment. Multidisciplinary approach is very much needed to fully develop the current and future value of ICI in clinical practice.

Original languageEnglish (US)
Article number456
JournalFrontiers in Oncology
Volume8
Issue numberNOV
DOIs
StatePublished - Jan 1 2018

Fingerprint

Kidney Neoplasms
Renal Cell Carcinoma
Biomarkers
Immunohistochemistry
Pharmaceutical Preparations
Patient Selection
Staining and Labeling
Therapeutics
Neoplasms
Survival
Immunotherapy
Pathology

Keywords

  • Immunological biomarker
  • Immunotherapy
  • PD-L1
  • Predictive biomarker
  • RCC subtypes
  • Renal cell carcinoma
  • Tumor mutation load

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Lopez-Beltran, A., Henriques, V., Cimadamore, A., Santoni, M., Cheng, L., Gevaert, T., ... Montironi, R. (2018). The identification of immunological biomarkers in kidney cancers. Frontiers in Oncology, 8(NOV), [456]. https://doi.org/10.3389/fonc.2018.00456

The identification of immunological biomarkers in kidney cancers. / Lopez-Beltran, Antonio; Henriques, Vanessa; Cimadamore, Alessia; Santoni, Matteo; Cheng, Liang; Gevaert, Thomas; Blanca, Ana; Massari, Francesco; Scarpelli, Marina; Montironi, Rodolfo.

In: Frontiers in Oncology, Vol. 8, No. NOV, 456, 01.01.2018.

Research output: Contribution to journalReview article

Lopez-Beltran, A, Henriques, V, Cimadamore, A, Santoni, M, Cheng, L, Gevaert, T, Blanca, A, Massari, F, Scarpelli, M & Montironi, R 2018, 'The identification of immunological biomarkers in kidney cancers', Frontiers in Oncology, vol. 8, no. NOV, 456. https://doi.org/10.3389/fonc.2018.00456
Lopez-Beltran A, Henriques V, Cimadamore A, Santoni M, Cheng L, Gevaert T et al. The identification of immunological biomarkers in kidney cancers. Frontiers in Oncology. 2018 Jan 1;8(NOV). 456. https://doi.org/10.3389/fonc.2018.00456
Lopez-Beltran, Antonio ; Henriques, Vanessa ; Cimadamore, Alessia ; Santoni, Matteo ; Cheng, Liang ; Gevaert, Thomas ; Blanca, Ana ; Massari, Francesco ; Scarpelli, Marina ; Montironi, Rodolfo. / The identification of immunological biomarkers in kidney cancers. In: Frontiers in Oncology. 2018 ; Vol. 8, No. NOV.
@article{f6c5baf7d9904f30bfc13edfad03bba3,
title = "The identification of immunological biomarkers in kidney cancers",
abstract = "The recent approval of several agents have revolutionized the scenario of therapeutic management of metastatic renal cell carcinoma (RCC) allowing us to reach important clinical end points with extended patients' survival. Actually, every new drug approved has represented an important step forward to the improvement of patient's survival. On the other hand, we now understand that RCC includes a large group of tumor entities, each of them with different genetic and mutational alterations, but also showing different clinical behavior; a reason behind the needs of subtype specific personalized approach to therapy of RCC. Immunotherapy is gradually becoming a key factor in the therapeutic algorithm for patients with locally advanced or metastatic RCC. Due to the combination of potent treatment success and potentially deadly adverse effects from immune checkpoint inhibitors (ICI), gathering prognostic and predictive information about FDA-indicated tumors seems to be prudent. Robust and reliable biomarkers are crucial for patient's selection of treatments with immunomodulatory drugs. PD-L1 expression is a poor prognostic factor and predictive of better responses from both PD-1 and PD-L1 inhibitors in a variety of tumor types including RCC. Each FDA approved PD-1/PD-L1 drug is paired with a PD-L1 Immunohistochemistry (IHC) assay. Thus, there is need for improved knowledge and application of PD-1/PD-L1 IHC biomarkers in daily practice. IHC staining appears in membranous fashion. The atezolizumab approved IHC assay is unique in that only immune cell staining is quantified for the use of this assay in RCC. A single biomarker for patient selection may not be feasible, given that immune responses are dynamic and evolve over time. Biomarker development for ICI drugs will likely require integration of multiple biologic components like PD-L1 expression, TILs and mutational load. New methodological approaches based on digital pathology may be relevant since they will allow recognition of the biomarker and to objectively quantitate its expression, and therefore might produce objective and reproducible cut-off assessment. Multidisciplinary approach is very much needed to fully develop the current and future value of ICI in clinical practice.",
keywords = "Immunological biomarker, Immunotherapy, PD-L1, Predictive biomarker, RCC subtypes, Renal cell carcinoma, Tumor mutation load",
author = "Antonio Lopez-Beltran and Vanessa Henriques and Alessia Cimadamore and Matteo Santoni and Liang Cheng and Thomas Gevaert and Ana Blanca and Francesco Massari and Marina Scarpelli and Rodolfo Montironi",
year = "2018",
month = "1",
day = "1",
doi = "10.3389/fonc.2018.00456",
language = "English (US)",
volume = "8",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "NOV",

}

TY - JOUR

T1 - The identification of immunological biomarkers in kidney cancers

AU - Lopez-Beltran, Antonio

AU - Henriques, Vanessa

AU - Cimadamore, Alessia

AU - Santoni, Matteo

AU - Cheng, Liang

AU - Gevaert, Thomas

AU - Blanca, Ana

AU - Massari, Francesco

AU - Scarpelli, Marina

AU - Montironi, Rodolfo

PY - 2018/1/1

Y1 - 2018/1/1

N2 - The recent approval of several agents have revolutionized the scenario of therapeutic management of metastatic renal cell carcinoma (RCC) allowing us to reach important clinical end points with extended patients' survival. Actually, every new drug approved has represented an important step forward to the improvement of patient's survival. On the other hand, we now understand that RCC includes a large group of tumor entities, each of them with different genetic and mutational alterations, but also showing different clinical behavior; a reason behind the needs of subtype specific personalized approach to therapy of RCC. Immunotherapy is gradually becoming a key factor in the therapeutic algorithm for patients with locally advanced or metastatic RCC. Due to the combination of potent treatment success and potentially deadly adverse effects from immune checkpoint inhibitors (ICI), gathering prognostic and predictive information about FDA-indicated tumors seems to be prudent. Robust and reliable biomarkers are crucial for patient's selection of treatments with immunomodulatory drugs. PD-L1 expression is a poor prognostic factor and predictive of better responses from both PD-1 and PD-L1 inhibitors in a variety of tumor types including RCC. Each FDA approved PD-1/PD-L1 drug is paired with a PD-L1 Immunohistochemistry (IHC) assay. Thus, there is need for improved knowledge and application of PD-1/PD-L1 IHC biomarkers in daily practice. IHC staining appears in membranous fashion. The atezolizumab approved IHC assay is unique in that only immune cell staining is quantified for the use of this assay in RCC. A single biomarker for patient selection may not be feasible, given that immune responses are dynamic and evolve over time. Biomarker development for ICI drugs will likely require integration of multiple biologic components like PD-L1 expression, TILs and mutational load. New methodological approaches based on digital pathology may be relevant since they will allow recognition of the biomarker and to objectively quantitate its expression, and therefore might produce objective and reproducible cut-off assessment. Multidisciplinary approach is very much needed to fully develop the current and future value of ICI in clinical practice.

AB - The recent approval of several agents have revolutionized the scenario of therapeutic management of metastatic renal cell carcinoma (RCC) allowing us to reach important clinical end points with extended patients' survival. Actually, every new drug approved has represented an important step forward to the improvement of patient's survival. On the other hand, we now understand that RCC includes a large group of tumor entities, each of them with different genetic and mutational alterations, but also showing different clinical behavior; a reason behind the needs of subtype specific personalized approach to therapy of RCC. Immunotherapy is gradually becoming a key factor in the therapeutic algorithm for patients with locally advanced or metastatic RCC. Due to the combination of potent treatment success and potentially deadly adverse effects from immune checkpoint inhibitors (ICI), gathering prognostic and predictive information about FDA-indicated tumors seems to be prudent. Robust and reliable biomarkers are crucial for patient's selection of treatments with immunomodulatory drugs. PD-L1 expression is a poor prognostic factor and predictive of better responses from both PD-1 and PD-L1 inhibitors in a variety of tumor types including RCC. Each FDA approved PD-1/PD-L1 drug is paired with a PD-L1 Immunohistochemistry (IHC) assay. Thus, there is need for improved knowledge and application of PD-1/PD-L1 IHC biomarkers in daily practice. IHC staining appears in membranous fashion. The atezolizumab approved IHC assay is unique in that only immune cell staining is quantified for the use of this assay in RCC. A single biomarker for patient selection may not be feasible, given that immune responses are dynamic and evolve over time. Biomarker development for ICI drugs will likely require integration of multiple biologic components like PD-L1 expression, TILs and mutational load. New methodological approaches based on digital pathology may be relevant since they will allow recognition of the biomarker and to objectively quantitate its expression, and therefore might produce objective and reproducible cut-off assessment. Multidisciplinary approach is very much needed to fully develop the current and future value of ICI in clinical practice.

KW - Immunological biomarker

KW - Immunotherapy

KW - PD-L1

KW - Predictive biomarker

KW - RCC subtypes

KW - Renal cell carcinoma

KW - Tumor mutation load

UR - http://www.scopus.com/inward/record.url?scp=85061781075&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061781075&partnerID=8YFLogxK

U2 - 10.3389/fonc.2018.00456

DO - 10.3389/fonc.2018.00456

M3 - Review article

AN - SCOPUS:85061781075

VL - 8

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - NOV

M1 - 456

ER -